A Multinational, Multicenter, Randomized, Open-label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women

Trial Profile

A Multinational, Multicenter, Randomized, Open-label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Ethinylestradiol/desogestrel (Primary) ; Ethinylestradiol
  • Indications Pregnancy
  • Focus Pharmacodynamics
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top